Cyrus Harmon - 29 Dec 2023 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Director
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
29 Dec 2023
Transactions value $
-$334,500
Form type
4
Filing time
02 Jan 2024, 17:30:06 UTC
Previous filing
01 Dec 2023
Next filing
02 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale -$299,250 -22,500 -2.43% $13.3 903,783 29 Dec 2023 Direct F1, F2
transaction OLMA Common Stock Sale -$35,250 -2,500 -0.28% $14.1 901,283 29 Dec 2023 Direct F1, F3
holding OLMA Common Stock 122,028 29 Dec 2023 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.
F2 The weighted average sale price for the transaction reported was $13.30, and the range of prices was between $13.15 and $13.87. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction reported was $14.10, and the range of prices was between $14.08 and $14.27. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.